Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 216

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Methotrexate treatment in juvenile localized scleroderma: A randomized, double-blind, placebo-controlled trial

Zulian, Francesco, Martini, Giorgia, Vallongo, Cristina, Vittadello, Fabio, Falcini, Fernanda, Patrizi, Annalisa, Alessio, Maria, Torre, Francesco La, Podda, Rosa A., Gerloni, Valeria, Cutrone, Mario, Belloni-Fortina, Anna, Paradisi, Mauro, Martino, Silvana, Perilongo, Giorgio·2011·Arthritis & Rheumatism

Abstract

OBJECTIVE: Juvenile localized scleroderma is a chronic progressive fibrotic disorder of the skin that causes permanent disability and aesthetic damage. This study was undertaken to assess the safety and efficacy of methotrexate (MTX) in the treatment of juvenile localized scleroderma. METHODS: In this double-blind study, patients with active juvenile localized scleroderma were randomized (2:1) to receive oral MTX (15 mg/m², maximum 20 mg) or placebo once weekly, for 12 months or until treatment failure. Both groups received oral prednisone (1 mg/kg/day, maximum 50 mg) for the first 3 months. A target lesion was evaluated clinically, with infrared thermography and using a computerized scoring system with skin score rate (SSR) evaluation. Response to treatment was defined as the absence of new lesions, SSR ≤ 1, and a decrease in lesion temperature of at least 10% compared to baseline. Treatment failure was defined as the occurrence of new lesions, SSR > 1, or increased lesion temperature. All analyses were done on the intent-to-treat population. RESULTS: Of the 85 patients screened, 70 (ages 6-17 years) were randomized (46 to the MTX group, 24 to the placebo group). The mean disease duration was 2.3 years. After an initial response in all patients, disease relapsed in 15 MTX-treated patients (32.6%) and 17 placebo-treated patients (70.8%) (P < 0.005). New lesions appeared in 3 MTX-treated patients (6.5%) versus 4 placebo-treated patients (16.7%). The mean SSR decreased from 1 to 0.79 in the MTX group and increased from 1 to 1.1 in the placebo group, and the mean target lesion temperature decreased by 44.4% in the MTX group versus 12.1% in the placebo group. Twenty-six patients in the MTX group (56.5%) and 11 patients in the placebo group (45.8%) developed mild side effects related to treatment. None of the side effects were severe enough to necessitate treatment discontinuation. CONCLUSION: Our findings indicate that MTX is efficacious in the treatment of juvenile localized scleroderma and is well tolerated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.30264

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 216

Metadata

Authors
Zulian, F., Martini, G., Vallongo, C., Vittadello, F., Falcini, F., Patrizi, A., Alessio, M., Torre, F. L., Podda, R. A., Gerloni, V., Cutrone, M., Belloni-Fortina, A., Paradisi, M., Martino, S., & Perilongo, G.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2011-06-29
Volume
63
Issue
7
Pages
1998-2006
ISSN
0004-3591 (ISSN-L)
OpenAlex
W2016759483
Cited by
216
References
1
FWCI
8.20
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Methotrexate treatment in juvenile localized scleroderma: A randomized, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1002/art.30264
The paper
Zulian, F., Martini, G., Vallongo, C., Vittadello, F., Falcini, F., Patrizi, A., Alessio, M., Torre, F. L., Podda, R. A., Gerloni, V., Cutrone, M., Belloni-Fortina, A., Paradisi, M., Martino, S., & Perilongo, G. (2011). Methotrexate treatment in juvenile localized scleroderma: A randomized, double-blind, placebo-controlled trial. Arthritis & Rheumatism. https://doi.org/10.1002/art.30264

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.